Tratamiento antirretroviral de la infección por el VIH - libdoc.who.int
Tratamiento antirretroviral de la infección por el VIH - libdoc.who.int
Tratamiento antirretroviral de la infección por el VIH - libdoc.who.int
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
146<br />
177. M Hull Moore D, Harris M, et al. A <strong>la</strong>mivudine (3TC)-based backbone in conjunction with a<br />
boosted protease inhibitor (PI) is sufficient to achieve virologic suppression in the<br />
presence of M184V mutations. 49th Interscience Conference on Antimicrobial Agents and<br />
Chemotherapy; 2009 September 12−15, 2009; San Francisco.<br />
178. Imaz A, <strong>de</strong>l Saz SV, Ribas MA, Curran A, Caballero E, Falco V, et al. Raltegravir, etravirine,<br />
and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrugresistant<br />
HIV-1 infection. J Acquir Immune Defic Syndr 2009;52(3):382-6.<br />
179. Hicks CB, DeJesus E, Sloan LM, Sension MG, Wohl DA, Liao Q, et al. Comparison of<br />
once-daily fos-amprenavir boosted with either 100 or 200 mg of ritonavir, in combination<br />
with abacavir/<strong>la</strong>mivudine: 96-week results from COL100758. AIDS Res Hum Retroviruses<br />
2009;25(4):395-403.<br />
180. Clotet B, B<strong>el</strong>los N, Molina JM, Cooper D, Goffard JC, Lazzarin A, et al. Efficacy and safety<br />
of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in<br />
POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet<br />
2007;369(9568):1169-78.<br />
181. Pozniak A, Opravil M, Beatty G, Hill A, <strong>de</strong> Bethune MP, Lefebvre E. Effect of bas<strong>el</strong>ine viral<br />
susceptibility on response to darunavir/ritonavir versus control protease inhibitors in<br />
treatment-experienced HIV type 1-infected patients: POWER 1 and 2. AIDS Res Hum<br />
Retroviruses 2008;24(10):1275-80.<br />
182. Rachlis A, Clotet B, Baxter J, Murphy R, Lefebvre E. Safety, tolerability, and efficacy of<br />
darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C coinfected<br />
patients in POWER 1 and 3. HIV clinical trials 2007;8(4):213-20.<br />
183. McKeage K, Perry CM, Keam SJ. Darunavir: a review of its use in the management of HIV<br />
infection in adults. Drugs 2009;69(4):477-503.<br />
184. Steigbig<strong>el</strong> RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al.<br />
Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med<br />
2008;359(4):339-54.<br />
185. Cooper DA, Steigbig<strong>el</strong> RT, Gat<strong>el</strong>l JM, Rockstroh JK, Kat<strong>la</strong>ma C, Yeni P, et al. Subgroup<br />
and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med<br />
2008;359(4):355-65.<br />
186. Schiller DS, Youssef-Bessler M. Etravirine: a second-generation nonnucleosi<strong>de</strong> reverse<br />
transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV. Clin Ther<br />
2009;31(4):692-704.<br />
187. Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, et al. High<br />
rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among<br />
treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS<br />
139 TRIO trial. Clin Infect Dis 2009;49(9):1441-9.<br />
TraTamienTo anTirreTroviral <strong>de</strong> <strong>la</strong> <strong>infección</strong> <strong>por</strong> <strong>el</strong> viH en adulTos y adolescenTes<br />
recomendaciones para un enfoque <strong>de</strong> salud pública
Change language